What does ARKOPHARMA BELUX do?

ARKOPHARMA BELUX is a wholesaler in Wavre. Public Limited, started on 23 December 1943, 1 establishment.

What is the address of ARKOPHARMA BELUX?

The registered office of ARKOPHARMA BELUX is located at Avenue Edison 13, 1300 Wavre.

Is ARKOPHARMA BELUX still active?

Yes. According to the CBE (30 October 2026) ARKOPHARMA BELUX is active, legal situation “Normale toestand”, started on 23 December 1943.

Is ARKOPHARMA BELUX registered on Peppol?

Yes, ARKOPHARMA BELUX is registered on the Peppol network with ID 0208:0401962852.

What is the enterprise number of ARKOPHARMA BELUX?

The enterprise number of ARKOPHARMA BELUX is BE0401962852.

When was ARKOPHARMA BELUX founded?

ARKOPHARMA BELUX was founded on 23 December 1943.

Who are the directors of ARKOPHARMA BELUX?

According to the 2024 annual accounts, the directors of ARKOPHARMA BELUX are: PATRICK VERBELEN, Olivier Ricq.

Is ARKOPHARMA BELUX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 1943; 4 annual accounts filed, latest fiscal year 2024; 2 directors known from the annual account.

How much profit did ARKOPHARMA BELUX make in 2024?

ARKOPHARMA BELUX posted a profit after taxes of € 68,891 in financial year 2024.

What is the revenue of ARKOPHARMA BELUX?

In its most recent annual accounts (2024), ARKOPHARMA BELUX reported revenue of € 8,581,305.

How much does an employee at ARKOPHARMA BELUX earn?

The average wage cost per full-time employee at ARKOPHARMA BELUX was € 88,900 in 2024: staff costs of € 1.8 million for 20.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ARKOPHARMA BELUX have?

According to the 2024 annual accounts, ARKOPHARMA BELUX has 20.8 full-time equivalents (FTE).

ARKOPHARMA BELUX (Public Limited) - Wavre - BE0401962852

Dossier ARKOPHARMA BELUX, printed on 30 October 2026 from databakkes.be/en/0401962852/arkopharma-belux. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 24.6 to 20.8.
Figures corrected NBB

Corrected annual account filed for 2021.
Late annual account NBB

Fiscal year 2024 was filed 410 days after the legal deadline.

Financials

Financial year 2024

ARKOPHARMA BELUX from Wavre, company number BE0401962852, closed financial year 2024 with a result of € 68,891 after tax. For that financial year ARKOPHARMA BELUX recorded revenue of € 8.6 million and equity of € 2 million. Compared with financial year 2023, the result moved from € 399,596 to € 68,891. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 14, 2026.

What it is worth Growing

€ 2 million

▲ 4% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 68,891

▼ 83% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 136,719

▲ 57% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 1.9 million.

People and assets in 2024

Full-time equivalents

20.8

▼ 1 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 2 million in 2024, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.8 million

▼ 7% vs 2023

€ 88,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 147,171

▼ 23% vs 2023

Of which on lease € 53,961.

Debts at end 2024

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 50,457

▼ 14% vs 2023

€ 8,409 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 2.1 million

▼ 16% vs 2023

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 123 days on average.

Taxes and wages

€ 307,111

▼ 6% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	€ 8,485,225 Revenue 2021: € 8,485,225 First fiscal year in the series	€ 8,645,026 Revenue 2022: € 8,645,026 ▲ 2% vs 2021 (€ 8,485,225) Favourable step	€ 8,516,593 Revenue 2023: € 8,516,593 ▼ 1% vs 2022 (€ 8,645,026) Unfavourable step	€ 8,581,305 Revenue 2024: € 8,581,305 ▲ 1% vs 2023 (€ 8,516,593) Favourable step	▲ 1%
Profit after taxes	€ 267,262 Profit after taxes 2021: € 267,262 First fiscal year in the series	€ 289,452 Profit after taxes 2022: € 289,452 ▲ 8% vs 2021 (€ 267,262) Favourable step	€ 399,596 Profit after taxes 2023: € 399,596 ▲ 38% vs 2022 (€ 289,452) Favourable step	€ 68,891 Profit after taxes 2024: € 68,891 ▼ 83% vs 2023 (€ 399,596) Unfavourable step	▼ 83%
Equity	€ 1,223,061 Equity 2021: € 1,223,061 First fiscal year in the series	€ 1,512,512 Equity 2022: € 1,512,512 ▲ 24% vs 2021 (€ 1,223,061) Favourable step	€ 1,912,108 Equity 2023: € 1,912,108 ▲ 26% vs 2022 (€ 1,512,512) Favourable step	€ 1,981,000 Equity 2024: € 1,981,000 ▲ 4% vs 2023 (€ 1,912,108) Favourable step	▲ 4%
Total debts	€ 3,505,345 Total debts 2021: € 3,505,345 First fiscal year in the series	€ 3,223,083 Total debts 2022: € 3,223,083 ▼ 8% vs 2021 (€ 3,505,345) Favourable step	€ 3,415,477 Total debts 2023: € 3,415,477 ▲ 6% vs 2022 (€ 3,223,083) Unfavourable step	€ 3,265,933 Total debts 2024: € 3,265,933 ▼ 4% vs 2023 (€ 3,415,477) Favourable step	▼ 4%
Cash	€ 224,041 Cash 2021: € 224,041 First fiscal year in the series	€ 297,031 Cash 2022: € 297,031 ▲ 33% vs 2021 (€ 224,041) Favourable step	€ 86,880 Cash 2023: € 86,880 ▼ 71% vs 2022 (€ 297,031) Unfavourable step	€ 136,719 Cash 2024: € 136,719 ▲ 57% vs 2023 (€ 86,880) Favourable step	▲ 57%
Land & buildings	€ 853,694 Land & buildings 2021: € 853,694 First fiscal year in the series	€ 795,169 Land & buildings 2022: € 795,169 ▼ 7% vs 2021 (€ 853,694) Unchanged	€ 786,823 Land & buildings 2023: € 786,823 ▼ 1% vs 2022 (€ 795,169) Unchanged	€ 839,883 Land & buildings 2024: € 839,883 ▲ 7% vs 2023 (€ 786,823) Unchanged	▲ 7%
Retained profit	€ 1,098,061 Retained profit 2021: € 1,098,061 First fiscal year in the series	€ 1,387,512 Retained profit 2022: € 1,387,512 ▲ 26% vs 2021 (€ 1,098,061) Favourable step	€ 1,787,108 Retained profit 2023: € 1,787,108 ▲ 29% vs 2022 (€ 1,387,512) Favourable step	€ 1,856,000 Retained profit 2024: € 1,856,000 ▲ 4% vs 2023 (€ 1,787,108) Favourable step	▲ 4%
Dividend	€ 250,000 Dividend 2021: € 250,000 First fiscal year in the series	€ 0 Dividend 2022: € 0 ▼ 100% vs 2021 (€ 250,000) Unchanged	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 75,685 Bank debt 2021: € 75,685 First fiscal year in the series	€ 67,276 Bank debt 2022: € 67,276 ▼ 11% vs 2021 (€ 75,685) Favourable step	€ 58,866 Bank debt 2023: € 58,866 ▼ 12% vs 2022 (€ 67,276) Favourable step	€ 50,457 Bank debt 2024: € 50,457 ▼ 14% vs 2023 (€ 58,866) Favourable step	▼ 14%
Balance sheet total	€ 4,821,029 Balance sheet total 2021: € 4,821,029 First fiscal year in the series	€ 4,823,370 Balance sheet total 2022: € 4,823,370 Unchanged (€ 4,821,029) Unchanged	€ 5,410,513 Balance sheet total 2023: € 5,410,513 ▲ 12% vs 2022 (€ 4,823,370) Unchanged	€ 5,325,013 Balance sheet total 2024: € 5,325,013 ▼ 2% vs 2023 (€ 5,410,513) Unchanged	▼ 2%
Employees (FTE)	23.1 Employees (FTE) 2021: 23.1 First fiscal year in the series	24.6 Employees (FTE) 2022: 24.6 ▲ 1.5 vs 2021 (23.1) Unchanged	21.8 Employees (FTE) 2023: 21.8 ▼ 2.8 vs 2022 (24.6) Unchanged	20.8 Employees (FTE) 2024: 20.8 ▼ 1 vs 2023 (21.8) Unchanged	▼ 1

Key figures of ARKOPHARMA BELUX, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to ARKOPHARMA BELUX?

What happened at ARKOPHARMA BELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 14, 2026 New annual accounts for financial year 2024: profit of € 68,891 (▼ 83% vs 2023). filed late Source: NBB ↗
2026 PATRICK VERBELEN stepped down as director. NBB
2026 Olivier Ricq stepped down as director. NBB
2023 PATRICK VERBELEN became a director. NBB
2023 Olivier Ricq became a director. NBB
Sep 24, 2002 New establishment in Wavre. KBO
Dec 23, 1943 Start of the company according to the CBE. KBO

In short

From € 267,262 profit in 2021 to € 68,891 profit in 2024.

Paid € 401,605 in corporate taxes since 2021.

Best year ever: 2023, with € 399,596 profit.

Paid out € 250,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2024 annual accounts

PATRICK VERBELEN

Director

since 2023 · until 2026

Olivier Ricq

Director

since 2023 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Edison 13

1300 Wavre

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0401.962.852

VAT number

BE 0401.962.852

Registered office

Avenue Edison 13, 1300 Wavre

Names & denominations

ARKOPHARMA BELUX

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

23 December 1943

Peppol

Active · Active since 17 Nov 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Groothandel in chemische producten voor industrieel gebruik

Groothandel in chemische producten

View on CBE Public ↗ Annual accounts (NBB) ↗